Neuropathy Target Esterase Is Required for Adult Vertebrate Axon Maintenance

The enzyme neuropathy target esterase (NTE) is present in neurons and deacylates the major membrane phospholipid, phosphatidylcholine (PtdCho). Mutation of the NTE gene or poisoning by neuropathic organophosphates—chemical inhibitors of NTE—causes distal degeneration of long spinal axons in humans. However, analogous neuropathological changes have not been reported in nestin-cre:NTEfl/fl mice with NTE-deficient neural tissue. Furthermore, altered PtdCho homeostasis has not been detected in NTE-deficient vertebrates. Here, we describe distal degeneration of the longest spinal axons in ∼3-week-old nestin-cre:NTEfl/fl mice and in adult C57BL/6J mice after acute dosing with a neuropathic organophosphate: in both groups early degenerative lesions were followed by swellings comprising accumulated axoplasmic material. In mice dosed acutely with organophosphate, maximal numbers of lesions, in the longest spinal sensory axon tract, were attained within days and were preceded by a transient rise in neural PtdCho. In nestin-cre:NTEfl/fl mice, sustained elevation of PtdCho over many months was accompanied by progressive degeneration and massive swelling of axons in sensory and motor spinal tracts and by increasing hindlimb dysfunction. Axonal lesion distribution closely resembled that in hereditary spastic paraplegia (HSP). The importance of defective membrane trafficking in HSP and the association of NTE with the endoplasmic reticulum—the starting point for the constitutive secretory pathway and transport of neuronal materials into axons—prompted investigation for a role of NTE in secretion. Cultured NTE-deficient neurons displayed modestly impaired secretion, consistent with neuronal viability and damage in vivo initially restricted to distal parts of the longest axons.

[1]  Christos Proukakis,et al.  Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms , 2008, The Lancet Neurology.

[2]  E. Koo,et al.  Amyloid Precursor Protein Trafficking, Processing, and Function* , 2008, Journal of Biological Chemistry.

[3]  Yi-Jun Wu,et al.  The homeostasis of phosphatidylcholine and lysophosphatidylcholine was not disrupted during tri-o-cresyl phosphate-induced delayed neurotoxicity in hens. , 2008, Toxicology.

[4]  J. Luzio,et al.  Spastin Couples Microtubule Severing to Membrane Traffic in Completion of Cytokinesis and Secretion , 2008, Traffic.

[5]  C. Blackstone,et al.  Atlastin GTPases are required for Golgi apparatus and ER morphogenesis. , 2008, Human molecular genetics.

[6]  H. Coon,et al.  Neuropathy target esterase gene mutations cause motor neuron disease. , 2008, American journal of human genetics.

[7]  S. Sakoda,et al.  Neuroaxonal Dystrophy Caused by Group VIA Phospholipase A2 Deficiency in Mice: A Model of Human Neurodegenerative Disease , 2008, The Journal of Neuroscience.

[8]  V. Bankaitis,et al.  The Sec14-superfamily and the regulatory interface between phospholipid metabolism and membrane trafficking. , 2007, Biochimica et biophysica acta.

[9]  J. Hauw,et al.  A mutation of spastin is responsible for swellings and impairment of transport in a region of axon characterized by changes in microtubule composition. , 2006, Human molecular genetics.

[10]  J. Luzio,et al.  Spastin and atlastin, two proteins mutated in autosomal-dominant hereditary spastic paraplegia, are binding partners. , 2006, Human molecular genetics.

[11]  P. Glynn,et al.  Loss of Swiss Cheese/Neuropathy Target Esterase Activity Causes Disruption of Phosphatidylcholine Homeostasis and Neuronal and Glial Death in Adult Drosophila , 2005, The Journal of Neuroscience.

[12]  M. Esiri,et al.  The extent of axonal loss in the long tracts in hereditary spastic paraplegia , 2004, Neuropathology and applied neurobiology.

[13]  H. Kato,et al.  An improved method for assaying phosphatidylcholine in mouse tissue. , 2004, Journal of pharmacological and toxicological methods.

[14]  P. Glynn,et al.  Neuropathy Target Esterase and Its Yeast Homologue Degrade Phosphatidylcholine to Glycerophosphocholine in Living Cells* , 2004, Journal of Biological Chemistry.

[15]  K. Akassoglou,et al.  Brain-specific deletion of neuropathy target esterase/swisscheese results in neurodegeneration. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Glynn,et al.  Placental Failure and Impaired Vasculogenesis Result in Embryonic Lethality for Neuropathy Target Esterase-Deficient Mice , 2004, Molecular and Cellular Biology.

[17]  P. Glynn,et al.  Protein Domains, Catalytic Activity, and Subcellular Distribution of Neuropathy Target Esterase in Mammalian Cells* , 2003, The Journal of Biological Chemistry.

[18]  E. Reid,et al.  Science in motion: common molecular pathological themes emerge in the hereditary spastic paraplegias , 2003, Journal of medical genetics.

[19]  P. Glynn Neural development and neurodegeneration: two faces of Neuropathy Target Esterase , 2000, Progress in Neurobiology.

[20]  A. Guidotti,et al.  Reelin secretion from glutamatergic neurons in culture is independent from neurotransmitter regulation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Glynn,et al.  Neuropathy target esterase: Immunolocalization to neuronal cell bodies and axons , 1998, Neuroscience.

[22]  S. E. Patton,et al.  Characterization of delayed neurotoxicity in the mouse following chronic oral administration of tri-o-cresyl phosphate. , 1985, Toxicology and applied pharmacology.

[23]  M. Lotti,et al.  Repeated small doses of a neurotoxic organophosphate , 1980, Archives of Toxicology.

[24]  M. Johnson,et al.  The delayed neurotoxic effect of some organophosphorus compounds. Identification of the phosphorylation site as an esterase. , 1969, The Biochemical journal.

[25]  C. Blackstone,et al.  Traffic accidents: molecular genetic insights into the pathogenesis of the hereditary spastic paraplegias. , 2006, Pharmacology & therapeutics.

[26]  T. Eagleton,et al.  The Significance Of Theory , 1990 .

[27]  J. Cavanagh The significance of the "dying back" process in experimental and human neurological disease. , 1964, International review of experimental pathology.